INNOVATIVE APPROACHES: DECENTRALIZED MANUFACTURING OF ATMPS

Cell therapy manufacturing today is dominated by the centralized model, leading to clinical success and commercialization of CAR-T products. The need for broader patient access to these therapies has driven a decentralized / point-of-care manufacturing approach. This panel aims to discuss scientific, technical, logistical, quality, and regulatory challenges that need to be addressed to make DM/POC cell therapy manufacturing a reality.
Moderator:
Daniel Palmacci, President, Cell and Gene Division, Lonza
Speakers:
Jason Foster, CEO, Ori Biotech
Fabian Gerlinghaus, Co-Founder and CEO, Cellares
Carol Houts, Chief Strategy Officer, Germfree
Christopher Vann, Chief Operating Officer, Autolus